Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI
Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships.
The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR) - a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses - the drug developer said on Thursday.
In a similar move, Danish rival Novo Nordisk (NOVOb.CO), opens new tab struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases.
Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations.
The drugmaker teamed up with Hong Kong-listed biotech Laekna (2105.HK), opens new tab last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle.
Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said.
As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said.
Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly.
Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
15 minutes ago
- Times
Brain chip could translate thoughts into speech
Technology with the ability to decode a person's inner thoughts and translate them into speech in real time has moved a step closer after the testing of a new brain implant, scientists have claimed. Researchers at Stanford University in California said that their device was able, with 74 per cent accuracy, to detect a person's 'inner speech' — where they imagined saying a specified set of words in their mind without any effort to physically utter them — and decipher which words they were thinking about. They said that it could represent a breakthrough for people with various forms of paralysis or impairments that prevent them from speaking unaided and could one day 'restore communication that is as fluent, natural and comfortable as conversational speech'.
The Independent
16 minutes ago
- The Independent
Here is how much Social Security payments are expected to jump in 2026
Social Security beneficiaries will likely receive bigger monthly checks come 2026 — but it still might not be enough to counteract inflation. That's according to the leading senior advocacy group, The Senior Citizens' League, which predicts the cost-of-living adjustment will rise 2.7 percent for next year when announced in October. The Social Security Administration announces a new COLA each year to ensure benefits for seniors keep up with inflation; if there is higher inflation, the monthly benefit also increases. "With the COLA announcement around the corner, seniors across America are holding their breath," the Senior Citizens' League Executive Director Shannon Benton said in a statement. 'While a higher COLA would be welcome because their monthly benefits will increase, many will be disappointed … Many seniors believe the COLA does not actually capture the inflation they experience.' The 2.7 percent increase predicted for 2026 is .2 percentage points more than the COLA for 2025. The 2025 COLA boosted benefits by about $49 a month for the average Social Security retiree's payment. Each fall, the Senior Citizens' League takes the average inflation measure by the Consumer Price Index for Urban Wage Earners and Clerical Workers for July, August and September to predict the COLA for the next year. The group's prediction for this year has risen each month since May, 'pointing to risks for resurgent inflation,' the Senior Citizens' League said. The inflation rate has held steady just at or around 3 percent since the start of the year, though experts predict it will rise later in the year as President Donald Trump's tariffs raise consumer prices. July's inflation rate of 2.7 percent comes in the final month before Americans can expect to see prices spike for everything from Irish Whiskey to Toyotas made in Japan to Brazilian coffee. Trump had initially rolled out tariffs on 'Liberation Day' in April before halting the plan after the stock market tumbled and the Treasury bond market spiked. The latest Consumer Price Index report from the Bureau of Labor Statistics seems to suggest that even though Trump paused many of his reciprocal tariffs, Americans are still feeling the effects. Even so, the White House says Americans have not been hurt by the tariffs. 'The Panicans continue to be proven wrong by the data – President Trump's tariffs are raking in billions of dollars, small business optimism is at a five-month high, and real wages are rising,' White House Press Secretary Karoline Leavitt said in a statement. 'The American people have rightfully put their trust in President Trump's America First agenda that is Making America Wealthy Again.' While Trump claims people won't be affected, a study from the Yale Budget Lab last week showed that consumers face an overall average tariff rate of 18.6 percent, the largest since the Great Depression.
Reuters
17 minutes ago
- Reuters
US FTC investigating Hims & Hers over advertising and cancellation practices, Bloomberg News reports
Aug 14 (Reuters) - The U.S. Federal Trade Commission is probing complaints about telehealth platform Hims & Hers (HIMS.N), opens new tab regarding its advertising and cancellation practices, according to a Bloomberg News report citing people familiar with the matter. Hims stock was down 5% in extended trading on Thursday. A spokesperson for Hims did not immediately respond to a request for comment. The company previously said it was cooperating with an unspecified FTC investigation after the agency demanded information from the company in October 2023. The FTC has cases ongoing against (AMZN.O), opens new tab and Uber (UBER.N), opens new tab over their subscription policies.
